Preoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine, Bevacizumab, and Radiotherapy

Sponsor
Austrian Breast & Colorectal Cancer Study Group
Study ID
NCT00671645
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • capecitabine, bevacizumab — DRUG
    Capecitabine 825 mg/m2 bid (on each therapy day of first 4 Therapy weeks) Bevacizumab 5 mg/kg weight; day 1, 15, 29

Study Details

* feasibility and tolerance of preoperative therapy with Bevacizumab in combination with Capecitabine and radiotherapy for patients with locally advanced, locally operable rectal carcinoma * collection of response rate (T- and M-downstaging, pathological complete remission)

Key Dates

First listed
May 5, 2008
Start date
Jul 31, 2008
Status verified
Oct 2020
Primary completion
Feb 27, 2009
Completion
Feb 27, 2009

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1

Primary Outcome Measure

feasibility and tolerance of preoperative therapy with Bevacizumab in combination with Capecitabine and radiotherapy for patients with locally advanced, locally operable rectal carcinoma [ Time Frame: descriptive evaluation ]

Related Studies